These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17633972)

  • 1. [Doubts as to the cardiovascular safety of rosiglitazone].
    Hoekstra JB; Bossuyt PM; de Vries JH
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1449-50. PubMed ID: 17633972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Doubts as to the cardiovascular safety of rosiglitazone].
    Wolffenbuttel BH
    Ned Tijdschr Geneeskd; 2007 Oct; 151(40):2236-7; author reply 2237. PubMed ID: 17969577
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular safety of rosiglitazone.
    Krall RL
    Lancet; 2007 Jun; 369(9578):1995-1996. PubMed ID: 17574083
    [No Abstract]   [Full Text] [Related]  

  • 4. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
    Mitka M
    JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
    [No Abstract]   [Full Text] [Related]  

  • 5. [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
    Erdmann E; Scherbaum WA
    MMW Fortschr Med; 2007 Dec; 149(49-50):49-50. PubMed ID: 18236983
    [No Abstract]   [Full Text] [Related]  

  • 6. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular risk and TZD: safe therapy for the elderly?
    Burt R; Townsend S; Armor B
    Consult Pharm; 2009 May; 24(5):392-4. PubMed ID: 19555148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of rosiglitazone in the treatment of type 2 diabetes.
    Singh S; Loke YK
    Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone and cardiovascular risk.
    Kaul S; Diamond GA
    Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone: seeking a balanced perspective.
    The Lancet
    Lancet; 2007 Jun; 369(9576):1834. PubMed ID: 17544746
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial: What have we lost in the wake of the rosiglitazone controversy?
    Zarich SW; Nesto RW
    Endocr Pract; 2009 Apr; 15(3):273-4. PubMed ID: 19364699
    [No Abstract]   [Full Text] [Related]  

  • 13. Diabetes drug safety update: Avandia and your heart.
    Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
    Loke YK; Kwok CS; Singh S
    BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone or pioglitazone in type 2 diabetes?
    de Vries CS; Russell-Jones DL
    BMJ; 2009 Aug; 339():b3076. PubMed ID: 19690344
    [No Abstract]   [Full Text] [Related]  

  • 16. In brief: rosiglitazone (Avandia) unbound.
    Med Lett Drugs Ther; 2014 Feb; 56(1435):12. PubMed ID: 24662977
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?
    Lindberg M; Astrup A
    Obes Rev; 2007 Sep; 8(5):381-4. PubMed ID: 17716295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
    Hiatt WR; Kaul S; Smith RJ
    N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
    Berthet S; Olivier P; Montastruc JL; Lapeyre-Mestre M
    BMC Clin Pharmacol; 2011 May; 11():5. PubMed ID: 21609444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone and cardiovascular disease: a diabetologist's perspective.
    Grant PJ
    Diab Vasc Dis Res; 2007 Jun; 4(2):75-6. PubMed ID: 17654437
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.